Neal James R

CIK 00016008656 companiesBERKELEY, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001600865

Recent Transactions

50 trades

Award
Processa Pharmaceuticals, Inc.$PCSA
Stock Options (Right to Buy)
2025-10-01+300,000→ 300,000 total
Award
Processa Pharmaceuticals, Inc.$PCSA
Restricted Stock Units
2025-10-01+100,000→ 100,000 total
Award
Processa Pharmaceuticals, Inc.$PCSA
Restricted Stock
2025-07-24+175,299→ 206,505 total
Award
Akari Therapeutics Plc$AKTX
Stock Option (Right to Buy)
2025-03-20+225,000→ 225,000 total
Award
Akari Therapeutics Plc$AKTX
Stock Option (Right to Buy)
2025-03-20+175,000→ 175,000 total
Award
Akari Therapeutics Plc$AKTX
Series A Warrants (Right to Buy)
2025-03-06$1.12/sh+4,464→ 4,464 total
Award
Akari Therapeutics Plc$AKTX
Series B Warrants (Right to Buy)
2025-03-06$1.12/sh+4,464→ 4,464 total
Award
Akari Therapeutics Plc$AKTX
American Depositary Shares representing Ordinary Shares
2025-03-06$1.12/sh+4,464→ 36,271 total
Award
Akari Therapeutics Plc$AKTX
Ordinary Shares, par value $0.0001 per share
2025-01-09$0.00/sh+8,000,000→ 32,216,000 total
Award
Akari Therapeutics Plc$AKTX
Ordinary Shares, par value $0.0001 per share
2024-12-23$0.00/sh+2,000,000→ 24,216,000 total
Conversion
Peak Bio, Inc.
Common Stock
2024-11-14+37,850→ 37,850 total
Disposition to Issuer
Peak Bio, Inc.
Warrant (Right to Purchase)
2024-11-14−33,340→ 0 total
Disposition to Issuer
Peak Bio, Inc.
Stock Option (Right to Buy)
2024-11-14−500,000→ 0 total
Disposition to Issuer
Peak Bio, Inc.
Common Stock
2024-11-14−37,850→ 0 total
Conversion
Peak Bio, Inc.
Convertible Notes
2024-11-14→ 0 total
Award
Processa Pharmaceuticals, Inc.$PCSA
Restricted Stock
2024-09-03+31,206→ 36,275 total
Award
Processa Pharmaceuticals, Inc.$PCSA
Restricted Stock
2024-09-03+31,206→ 31,206 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Restricted Stock Units
2024-02-09−5,100→ 0 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Common Stock Options
2024-02-09−6,880→ 0 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Common Stock Options
2024-02-09−12,160→ 0 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Common Stock Options
2024-02-09+6,880→ 6,880 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Common Stock Options
2024-02-09+12,160→ 12,160 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Restricted Stock Units
2024-02-09−5,820→ 0 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Common Stock, par value $0.01
2024-02-09+5,820→ 10,920 total
Exercise/Conversion
PALISADE BIO, INC.$PALI
Common Stock, par value $0.01
2024-02-09+5,100→ 5,100 total
Award
PALISADE BIO, INC.$PALI
Common Stock Options
2023-11-21+6,880→ 6,880 total
Award
PALISADE BIO, INC.$PALI
Restricted Stock Units
2023-11-21+5,820→ 5,820 total
Award
Processa Pharmaceuticals, Inc.$PCSA
Restricted Stock
2023-06-27+101,365→ 101,365 total
Exercise/Conversion
Processa Pharmaceuticals, Inc.$PCSA
Common Stock
2023-06-27+14,407→ 14,407 total
Exercise/Conversion
Processa Pharmaceuticals, Inc.$PCSA
Restricted Stock
2023-06-27−14,407→ 0 total
Award
PALISADE BIO, INC.$PALI
Common Stock Options
2023-06-11+12,160→ 12,160 total
Award
PALISADE BIO, INC.$PALI
Restricted Stock Units
2023-06-11+5,100→ 5,100 total
Award
Peak Bio, Inc.
Convertible Notes
2023-04-28$20004.00/sh
Award
Peak Bio, Inc.
Warrant (Right to Purchase)
2023-04-28+33,340→ 33,340 total
Award
Processa Pharmaceuticals, Inc.$PCSA
Restricted Stock
2022-07-19+17,797→ 17,797 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Common Stock
2022-07-15$4.03/sh+25,000→ 36,822 total
Sale
XOMA Royalty Corp$XOMA
Common Stock
2022-07-15$31.19/sh−3,212→ 12,727 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Stock Option (Right to Buy)
2022-07-15−25,000→ 218,056 total
Sale
XOMA Royalty Corp$XOMA
Common Stock
2022-07-15$31.86/sh−905→ 11,822 total
Sale
XOMA Royalty Corp$XOMA
Common Stock
2022-07-15$29.55/sh−20,883→ 15,939 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Stock Option (Right to Buy)
2022-03-23−1,111→ 102,800 total
Sale
XOMA Royalty Corp$XOMA
Common Stock
2022-03-23$30.02/sh−1,111→ 11,822 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Common Stock
2022-03-23$4.03/sh+1,111→ 12,933 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Stock Option (Right to Buy)
2022-03-22−2,339→ 103,911 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Common Stock
2022-03-22$4.03/sh+2,339→ 14,161 total
Sale
XOMA Royalty Corp$XOMA
Common Stock
2022-03-22$30.02/sh−2,339→ 11,822 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Common Stock
2022-03-21$4.03/sh+50,000→ 61,822 total
Sale
XOMA Royalty Corp$XOMA
Common Stock
2022-03-21$29.00/sh−50,000→ 11,822 total
Exercise/Conversion
XOMA Royalty Corp$XOMA
Stock Option (Right to Buy)
2022-03-21−50,000→ 106,250 total
Award
XOMA Royalty Corp$XOMA
Non-Qualified Share Option (right to buy)
2021-12-21+60,000→ 60,000 total

Companies

Recent Filings

Address

C/O XOMA CORPORATION 2910 SEVENTH STREET

BERKELEY, CA, 94710

View on SEC.gov